Search results
Results from the WOW.Com Content Network
Depakote (valproic acid/sodium valproate) – an antiepileptic and mood stabilizer used to treat bipolar disorder, neuropathic pain and others; sometimes called an antimanic medication. Depakene is the trade name for the same drug prepared without sodium. Desyrel – an atypical antidepressant used to treat depression and insomnia
Oxcarbazepine, sold under the brand name Trileptal among others, is a medication used to treat epilepsy. [ 3 ] [ 5 ] For epilepsy it is used for both focal seizures and generalized seizures . [ 6 ] It has been used both alone and as add-on therapy in people with bipolar disorder who have had no success with other treatments.
Some rebound or withdrawal adverse effects, ... and the related compound oxcarbazepine (Trileptal) Valproic acid, and salts (Depakene, Depakote) Lamotrigine (Lamictal ...
Antidepressant discontinuation syndrome, also called antidepressant withdrawal syndrome, is a condition that can occur following the interruption, reduction, or discontinuation of antidepressant medication following its continuous use of at least a month. [5]
Where risks or harms is the reason for withdrawal, this will usually have been prompted by unexpected adverse effects that were not detected during Phase III clinical trials, i.e. they were only made apparent from postmarketing surveillance data collected from the wider community over longer periods of time.
The Maternal Outcomes and Neurodevelopmental Effects of Antiepileptic Drugs (MONEAD) study showed that most blood concentrations in breastfed infants of mothers taking carbamazepine, oxcarbazepine, valproate, levetiracetam, and topiramate were quite low, especially in relationship to the mother's level and what the fetal level would have been ...
Generally, tapering is done is to avoid or minimize withdrawal symptoms that arise from neurobiological adaptation to the drug. [1] [2] Prescribed psychotropic drugs that may require tapering due to this physical dependence include opioids, [3] [4] [5] selective serotonin reuptake inhibitors, [6] antipsychotics, [7] anticonvulsants, [8] and ...
Novartis made a settlement of $422.5 million, including a $185 million criminal fine and forfeiture for the off-label promotion of the anti-epilepsy drug Trileptal. [29] Trileptal was approved by the FDA to treat partial seizures, but was allegedly promoted to treat pain and some psychiatric conditions.